The chart below appeared recently in our exclusive Digital Health Briefing, a daily email newsletter available only to subscribers.
| | The chart below appeared recently in our exclusive Digital Health Briefing, a daily email newsletter available only to subscribers. Right now, you can try the Briefing for just $1! Read on for a preview of the content you can expect as a Briefing subscriber. |
| | | Digital therapeutics (DTx) developer Pear examined the efficacy of and cost-savings opportunity tied to its solution for opioid use disorder, Reset-o—and found that it reduced inpatient and ER visits, saving payers $2,150 per patient over the course of 15 months, per MedCity News. Reset-o acts as a complement to traditional medication—specifically buprenorphine, which treats opioid addiction—and provides users with app-based tasks that foster skills for managing and understanding addiction treatment.
Reset-o stands out in the DTx space—it was the first digital treatment of its kind to earn the FDA’s greenlight. The solution—codeveloped with pharma giant Novartis—hit a milestone when it won FDA clearance in December 2018, making it the first DTx for opioid use disorder to do so. Since then, it’s built out its portfolio of payer partners offering the service to members.
The opioid epidemic is worsening in the US—placing an emphasis on new innovations that could help healthcare stakeholders address and counteract it. The coronavirus pandemic has exacerbated the US’ opioid addiction crisis. Forty states have reported increased opioid use-related deaths amid the pandemic, according to the AMA—following the US’ highest-recorded fatality number of any year in 2019. That means there’s a need for more innovative, accessible solutions that curb the crisis and take a more holistic approach to treatment. Tech-focused companies like Google sister company Verily—which colaunched a data-driven opioid treatment center in 2019—are already leaping into the space to apply big data and analytics to mitigate the crisis. And while Reset-o remains the only FDA-cleared prescription DTx for opioid use disorder on the market, we doubt it’ll remain alone for long. |
|---|
|  | | |
|
| |
| |
